Investigating biochemical and molecular factors in soft tissue sarcoma
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
This study is trying to find out if certain markers in tissue and blood samples from patients with soft tissue sarcoma can help predict how well they will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Trial ID | NCT00579566 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze normal and sarcoma cells by utilizing human tissue samples obtained from patients undergoing procedures to remove tissue. The research will focus on identifying specific biochemical, proteomic, epigenetic, and molecular genetic markers that can predict clinical outcomes and responsiveness to therapy in soft tissue sarcoma. Blood samples will also be collected to measure biochemical factors that may aid in understanding the behavior of sarcoma. The study will utilize leftover tissue from diagnostic or therapeutic procedures, ensuring minimal additional burden on participants.
Who should consider this trial
Good fit: Ideal candidates include patients with known or suspected sarcoma who are undergoing tissue removal for diagnostic or therapeutic purposes.
Not a fit: Patients without sarcoma or those who do not have tissue available for analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with soft tissue sarcoma.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for sarcoma, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes. * Patients will be entered without preference for any particular racial/ethnic group or gender. * Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy. * Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube Exclusion Criteria: \- None
Where this trial is running
Basking Ridge, New Jersey and 6 other locations
- Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up) — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth (Consent and Followup) — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Bergen (Consent and Follow up) — Montvale, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Commack (Consent and Follow-Up) — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester (Consent and Followup) — Harrison, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Nassau (Consent and Followup) — Rockville Centre, New York, United States (Recruiting)
Study contacts
- Principal investigator: Singer Singer, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Samuel Singer, MD
- Phone: 212-639-2940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.